The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Ascendis Pharma A/S | SPONSORED ADS | 04351P101 | 12,428 | 133,691 | SH | SOLE | 133,691 | 0 | 0 | ||
Cymabay Therapeutics, Inc. | COM | 23257D103 | 4,843 | 1,641,804 | SH | SOLE | 1,641,804 | 0 | 0 | ||
Natera, Inc. | COM | 632307104 | 5,641 | 159,160 | SH | SOLE | 159,160 | 0 | 0 | ||
Verona Pharma PLC. | SPONSORED ADS | 925050106 | 4,656 | 1,111,112 | SH | SOLE | 1,111,112 | 0 | 0 |